Articles tagged "Immunoglobulins (Ig)"

2020 American Transplant Congress
Recurrence of IgA Nephropathy after Kidney Transplantation – Tango Multicenter Study
A. Uffing¹, P. Cravedi², L. V. Riella¹
¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Icahn School of Medicine at Mount Sinai, New York, NY
*Purpose: In patients with IgA nephropathy as the cause of ESKD, IgA deposits can recur in the transplanted kidney. However,the incidence and clinical impact of…
2020 American Transplant Congress
IgA Nephropathy Outcomes after Kidney Transplantation in an Early Corticosteroid Withdrawal Center
S. Kurian¹, S. Spierling², B. Barrick¹, J. Rice¹, J. Case¹, C. Marsh¹
¹Scripps Center for Organ and Cell Transplantation, La Jolla, CA, ²Scripps Whittier Diabetes Institute, La Jolla, CA
*Purpose: IgA nephropathy (IgAN) is the most frequent biopsy-proven primary glomerular disease. Recurrent IgA after transplantation often leads to allograft loss. A lower risk of…
2020 American Transplant Congress
Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression During the First Year Post-Transplant (<1yr Tx) Increases Risk for CMV Infection Through Inhibition of Anti-CMV Humoral Immunity
B. Shin, N. Ammerman, S. Sethi, A. Vo, S. C. Jordan, M. Toyoda
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have shown a higer CMV infection rate in kidney Tx patients (KTx Pts) who were converted to BLT 1yr post-Tx. Viral infections are…
2020 American Transplant Congress
Single Center Experience of Valganciclovir and Adjunctive CMV IVIG for the Treatment of CMV Infection in Lung Transplant Recipients
A. A. Fernandez¹, N. Sinha², M. Loebe², J. Glaze², S. Manickavel², M. Fernandez², T. Pastrana², J. Simkins³, J. Camargo³, M. I. Morris³, L. Abbo³, Y. Natori³
¹Infectious Disease, University of Miami Jackson Memorial Hospital, Miami, FL, ²University of Miami Jackson Memorial Hospital, Miami, FL, ³Transplant Infectious Disease, University of Miami Jackson Memorial Hospital, Miami, FL
*Purpose: Cytomegalovirus(CMV) infection happens commonly and causes significant morbidity in lung transplant (LTx) recipients. The use of CMV hyperimmune globulin (CMVIg) as an adjunctive treatment…
2020 American Transplant Congress
In-Vivo Application of Ides (Imlifidase) in Nonhuman Primates Results in Xenoreactive Desensitization: A Novel Anti-Humoral Therapy
B. P. Lovasik¹, A. J. Matar¹, D. A. Faber¹, D. V. Mathews¹, C. Breeden¹, S. C. Kim¹, A. J. Tector², A. Robertson³, C. Kjellman³, A. B. Adams¹
¹Emory University School of Medicine, Atlanta, GA, ²University of Miami, Miami, FL, ³HANSA Biopharma, Lund, Sweden
*Purpose: Antibody-mediated rejection is a formidable barrier to xenograft survival. A novel anti-humoral IdeS therapy, which cleaves serum IgG, represents a promising therapy to reduce…
2020 American Transplant Congress
Pretransplant BKV-IgG Serostatus and BKV-Specific ELISPOT Assays for the Prediction of BKV Infection
H. Bae¹, J. Jang¹, H. Lee², S. Yun¹, E. Oh³
¹Department of Biomedical Science, Graduate School, Catholic University of Korea, Seoul 137-040, Korea, Republic of, ²Department of Laboratory Medicine, Catholic Kwandong University of Korea, Incheon, Korea, Republic of, ³Department of Laboratory Medicine, Catholic University of Korea, Seoul 137-040, Korea, Republic of
*Purpose: BK Polyomavirus (BK) can lead to major infectious complications and damage to the graft in kidney transplantation (KT). We investigated whether pretransplant BK serostatus…
2020 American Transplant Congress
Carfilzomib-Based Desensitization: Effects on HLA, Non-HLA, Auto, and Antiviral Antibodies
S. Tremblay¹, E. Portwood¹, A. R. Shields², R. R. Alloway¹, P. A. Brailey¹, E. Woodle¹
¹U Cincinnati, Cincinnati, OH, ²U Cincinnati, Christ Hospital, Cincinnati, OH
*Purpose: An important question in plasma cell (PC) therapies is the specificity of therapy for PC populations. It is known that plasmablast populations are exquisitely…
2020 American Transplant Congress
Novel micro-RNA and Microbiome Signature Profiles as Biomarkers for Predicting the Risk of Autoimmune Type 1 Diabetes Development
P. Chhabra¹, G. Ricardo¹, A. Spano², V. Mas¹, M. Timko², K. Brayman¹
¹Dept of Surgery, University of Virginia Health System, Charlottesville, VA, ²Dept of Biology, University of Virginia Health System, Charlottesville, VA
*Purpose: To identify reliable microRNA (miRNA) and microbiome biomarkers for predicting risk of autoimmune beta-cell destruction in type 1 diabetes (T1D) and to investigate alterations…
2020 American Transplant Congress
Renal Safety of Entecavir and Tenofovir with Hepatitis B Immunoglobulin in Liver Transplant Patients
J. Lee¹, E. Kim¹, S. Yang¹, D. Kim², S. Kim¹, J. Park³, H. Choi⁴, B. Kim³, D. Joo¹, M. Kim¹, S. Kim¹, J. Lee¹
¹Department of Transplantation Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, ²Department of Surgery, Wonju Severance Hospital, Yonsei University College of Medicine, Wonju, Korea, Republic of, ³Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, ⁴Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
*Purpose: Combination of potent nucleos(t)ide analougues (NAs) and hepatitis B immunoglobulin is recommended after liver transplantation for the prevention of hepatitis B virus (HBV) recurrence.…
2020 American Transplant Congress
Long-Term Islet Allo- and Xenograft Survival is Promoted by Immunoglobulin M Immunotherapy
M. Ma, K. Brayman, P. Chhabra
Department of Surgery, University of Virginia Health System, Charlottesville, VA
*Purpose: To investigate if islet allo- and xenotransplant rejection is mitigated by IgM immunotherapy.*Methods: a) New onset diabetic NOD mice (n=14) were treated with IgM…

1
2
3
…
6
Next Page »